Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Thurlimann B(2009)Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of international breast cancer study group trial 11-93 Breast Cancer Res Treat 113 137-144

Price KN(2006)Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 1658-1667

Gelber RD(2007)HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 357 1496-1506

Holmberg SB(2011)Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial Lancet Oncol 12 631-641

Crivellari D(2009)Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 1319-1329

Colleoni M(2006)Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726-3734

Collins J(2010)Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 55-65

Forbes JF(2004)A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817-2826

Castiglione-Gertsch M(2006)A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients Breast Cancer Res 8 R25-3118

Coates AS(2010)Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population Cancer 116 3112-2014

Thurlimann B(2009)Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of international breast cancer study group trial 11-93 Breast Cancer Res Treat 113 137-144

Price KN(2006)Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 1658-1667

Gelber RD(2007)HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 357 1496-1506

Holmberg SB(2011)Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial Lancet Oncol 12 631-641

Crivellari D(2009)Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 1319-1329

Colleoni M(2006)Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726-3734

Collins J(2010)Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 55-65

Forbes JF(2004)A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817-2826

Castiglione-Gertsch M(2006)A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients Breast Cancer Res 8 R25-3118

Coates AS(2010)Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population Cancer 116 3112-2014